Effective March 1st, 2023, Dr. Timo Lebold and Felix Bunde have been appointed to the management of GBA Medical Device Services GmbH. By this, long-term experience in the medical device industry is combined with experience in business administration, strategic development, controlling, and project management.

Dr. Lebold and Mr. Bunde will further support the growth of GBA Medical Device Services GmbH to enable continuing of providing the high-quality service that defines MDS.

In terms of the daily business operations, nothing has changed for you. Test reports as well as other official documents will be updated successively. There is no need to adapt the contracts.

Covid19 changed many of the established procedures. Study designs also had to be adapted to the new reality of conducting clinical trials. This was accompanied by an increase in the integration and use of digital structures in clinical trials. Patients could no longer visit the trial centre, so telephone and video visits were introduced. Monitors could not visit the trial sites, so new ways had to be found to ensure data quality.

Some of these innovations have proven to be helpful and beneficial to trials, for example by facilitating patient recruitment, increasing patient retention and saving time and money. These are benefits that are hard to resist, and the trend is moving away from traditional trials and towards decentralised or hybrid trials.

However, with new concepts come new questions and obstacles that need to be considered and solved. LKF, ABF and AMEDON, have worked together in a workshop to develop solutions that we adapt to our customers' needs.

Memnoniella echinata is a mold with worldwide distribution that has often been isolated from clothing or carpets indoors. The species is not among the officially recognized indoor moisture indicators. An increased detection of Memnoniella echinata can therefore be an indication of increased moisture in the interior. Concrete data on the aW value are not known. According to TRBA 460, the mold species Memnoniella echinata is classified in biological risk group 1. Thus, there is no known increased risk of infection for humans.

PFAS analysis is a routine accredited parameter by GBA Group, for which we have developed a proprietary method. With our HPLC-MS/MS method, we can detect PFAS at concentrations as low as 0.1 µg/kg, which means that we can also easily control the maximum levels for PFAS in certain foods that have come into force in the EU since 01.01.2023. Our comprehensive accreditation covers validated matrices such as meat, fish, eggs, vegetables and milk.

The pressure on quality managers in the food industry has been increasing for years, more and more additional, complex issues are coming their way. GBA BeNeLux (Lavetan), nuTIQ and QAssurance are joining forces and making the lives of quality managers easier, by offering customized solutions with their complementary services and expertise.